Literature DB >> 13059717

Treatment of cardiogenic shock by prolonged administration of norepinephrine.

A ENGLISH.   

Abstract

Entities:  

Keywords:  ARTERENOL/therapeutic use; MYOCARDIAL INFARCT/complications; SHOCK

Mesh:

Substances:

Year:  1953        PMID: 13059717      PMCID: PMC1822838     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Clinical observations on a new epinephrine-like compound, methoxamine.

Authors:  M H NATHANSON; H MILLER
Journal:  Am J Med Sci       Date:  1952-03       Impact factor: 2.378

2.  Intraarterial infusion in the treatment of shock resulting from coronary occlusion.

Authors:  E F BERMAN; L C AKMAN
Journal:  Am Heart J       Date:  1952-02       Impact factor: 4.749

3.  The potentiating effect of ACTH and of cortisone of pressor response to intravenous infusion of L-nor-epinephrine.

Authors:  G S KURLAND; A S FREEDBERG
Journal:  Proc Soc Exp Biol Med       Date:  1951-10

4.  Treatment of shock in recent myocardial infarction by intra-arterial transfusion.

Authors:  E N SILBER; B D LEVIN; G H BECKER; R C LEVY
Journal:  J Am Med Assoc       Date:  1951-12-22

5.  Effect of cortisone on experimentally produced myocardial infarction; preliminary report.

Authors:  A S JOHNSON; S R SCHEINBERG; R GERISCH; H C SALTZSTEIN
Journal:  Harper Hosp Bull       Date:  1951 Nov-Dec

6.  Treatment of hypotension accompanying myocardial infarction; use of a pressor substance.

Authors:  B L BROFMAN; H K HELLERSTEIN; W H CASKEY
Journal:  J Lab Clin Med       Date:  1950-11

7.  The clinical use of norepinephrine in the treatment of shock accompanying myocardial infarction and other conditions.

Authors:  G S KURLAND; M MALACH
Journal:  N Engl J Med       Date:  1952-09-11       Impact factor: 91.245

8.  Shock accompanying myocardial infarction: treatment with pressor amines amines.

Authors:  H K HELLERSTEIN; B L BROFMAN; W H CASKEY
Journal:  Am Heart J       Date:  1952-09       Impact factor: 4.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.